Key Abstracts in GU Cancers at ASCO24

Key Abstracts in GU Cancers at ASCO24

Up next

Groundbreaking Results Shift Treatment Paradigm in High-Risk Smoldering Multiple Myeloma

Dr. Monty Pal speaks with internationally acclaimed hematologists Dr. Vincent Rajkumar and Dr. Saad Usmani about the AQUILA trial in high-risk smoldering multiple myeloma, as well as advances in CAR-T and other evolving treatment strategies in the myeloma space. TRANSCRIPT Dr. Mo ...  Show more

Navigating Therapeutic Advances in EGFR-Mutated NSCLC

Dr. Monty Pal and Dr. Vamsi Velcheti discuss the evolving treatment landscape in EGFR-mutated non-small cell lung cancer, including landmark trials like FLAURA2, novel drug therapies, and the growing importance of ctDNA and MRD testing. TRANSCRIPT Dr. Monty Pal: Hello, and welcom ...  Show more

Recommended Episodes

Podcast 300: NADIM II trial offers “quite exciting” results in lung cancer
Clinical Conversations

A VIDEO RECORDING OF THIS INTERVIEW IS AVAILABLE HERE.

We’re back with another interview from this year’s IASLC conference.

This time, Christine Sadlowski and Dr. Julia Rotow interview Dr. Mar ...

  Show more

Treatment of Metastatic Colorectal Cancer Guideline
ASCO Guidelines

An interview with Dr. Van Morris from The University of Texas MD Anderson Cancer Center in Houston, TX and Dr. Cathy Eng from Vanderbilt-Ingram Cancer Center in Nashville, TN, co-chairs on "Treatment of Metastatic Colorectal Cancer: ASCO Guideline." Dr. Morris and Dr. Eng review ...  Show more

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers Guideline
ASCO Guidelines

Dr. Emrullah Yilmaz reviews the latest evidence and recommendations for health care providers on biomarker testing and immunotherapy for head and neck cancers. He discusses the ASCO Expert Panel's recommendations for biomarkers for the selection of patients with head and neck squ ...  Show more

Management of Stage III NSCLC Rapid Recommendation Update
ASCO Guidelines

Dr. Navneet Singh joins us again, this time to discuss the rapid recommendation update for stage III non-small cell lung cancer, incorporating updated data presented at the 2023 ASCO Annual Meeting. He discusses the new trials that prompted the guideline update and updated recomm ...  Show more